Current Value
$78.691 Year Return
Current Value
$78.691 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
WAL | -0.04% | $9.41B | +22.05% | 1.77% |
MVO | 0.04% | $69.92M | -35.18% | 21.79% |
JACK | -0.06% | $400.81M | -58.89% | 6.15% |
FF | -0.07% | $179.16M | -21.04% | 5.84% |
AMC | -0.07% | $1.43B | -38.27% | 0.00% |
FFIN | -0.07% | $5.32B | +15.57% | 1.97% |
WABC | -0.08% | $1.36B | -3.76% | 3.43% |
LPX | 0.08% | $6.33B | +4.96% | 1.19% |
HAFC | -0.09% | $792.77M | +45.05% | 4.04% |
TOWN | 0.11% | $2.69B | +18.38% | 2.85% |
PLRX | 0.12% | $89.01M | -89.04% | 0.00% |
AUTL | -0.12% | $705.27M | -40.45% | 0.00% |
CHCO | 0.12% | $1.82B | +9.87% | 2.46% |
TRN | -0.13% | $2.26B | -7.99% | 4.24% |
STBA | 0.14% | $1.52B | +8.24% | 3.42% |
ACET | -0.15% | $64.40M | -36.70% | 0.00% |
MSEX | 0.15% | $998.16M | -4.33% | 2.43% |
STEL | 0.16% | $1.60B | +22.96% | 1.76% |
CARM | -0.16% | $18.84M | -64.22% | 0.00% |
IBEX | 0.16% | $400.24M | +78.15% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
F | 49.40% | $47.24B | -15.17% | 5.04% |
BSX | 45.65% | $154.35B | +33.72% | 0.00% |
WM | 45.48% | $92.27B | +6.16% | 1.38% |
INVH | 41.71% | $19.80B | -8.42% | 3.56% |
MXL | 41.66% | $1.29B | -38.03% | 0.00% |
ITGR | 41.03% | $4.17B | -0.36% | 0.00% |
SYK | 40.82% | $149.60B | +19.14% | 0.85% |
ORN | 40.81% | $333.84M | -17.58% | 0.00% |
ROL | 39.27% | $27.01B | +15.36% | 1.16% |
STM | 38.90% | $28.16B | -24.54% | 1.12% |
RBBN | 38.76% | $711.47M | +4.95% | 0.00% |
RSG | 37.91% | $76.30B | +21.36% | 0.95% |
ISRG | 37.34% | $185.10B | +18.11% | 0.00% |
TER | 37.07% | $15.28B | -40.30% | 0.49% |
LKQ | 36.60% | $9.91B | -12.39% | 3.12% |
RCL | 35.47% | $92.88B | +103.93% | 0.73% |
KALU | 35.08% | $1.43B | -7.02% | 3.46% |
HON | 33.82% | $153.00B | +10.36% | 1.89% |
ALGN | 32.69% | $14.45B | -17.05% | 0.00% |
BKNG | 32.60% | $187.63B | +41.05% | 0.64% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LTM | -77.19% | $12.57B | -95.57% | 2.41% |
POAI | -35.99% | $7.69M | -27.93% | 0.00% |
GSHD | -35.81% | $2.42B | +63.03% | 0.00% |
RES | -26.82% | $1.10B | -19.42% | 3.26% |
NOC | -21.40% | $75.00B | +20.65% | 1.63% |
HNI | -18.60% | $2.42B | +8.21% | 2.55% |
FBNC | -18.50% | $1.96B | +31.19% | 1.88% |
SBSI | -17.19% | $941.17M | +4.85% | 4.62% |
MOH | -17.09% | $11.87B | -22.90% | 0.00% |
POOL | -16.33% | $11.32B | -7.91% | 1.60% |
IMAX | -16.20% | $1.50B | +61.65% | 0.00% |
MCRI | -16.03% | $1.62B | +25.38% | 1.38% |
VKTX | -15.69% | $3.55B | -46.73% | 0.00% |
FMNB | -14.80% | $534.50M | +3.65% | 4.77% |
OII | -14.68% | $2.12B | -19.40% | 0.00% |
TR | -13.73% | $2.60B | +24.71% | 1.02% |
NEUE | -13.62% | $60.89M | +31.91% | 0.00% |
RTX | -13.07% | $199.43B | +46.90% | 1.71% |
CLB | -12.75% | $583.22M | -45.89% | 0.32% |
PLXS | -12.52% | $3.61B | +18.02% | 0.00% |
Double maintains 12 strategies that include EW - Edwards Lifesciences Corp.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SGOV | 0.06% | $50.94B | 0.09% |
TLH | -0.07% | $11.45B | 0.15% |
VTIP | 0.18% | $15.19B | 0.03% |
GBIL | -0.20% | $6.37B | 0.12% |
FMF | -0.22% | $161.67M | 0.95% |
FTXG | -0.22% | $22.31M | 0.6% |
IBMS | 0.24% | $89.71M | 0.18% |
EDV | -0.26% | $3.40B | 0.05% |
DBO | 0.29% | $228.22M | 0.77% |
IGOV | 0.34% | $1.25B | 0.35% |
BSV | -0.38% | $38.00B | 0.03% |
TLT | -0.42% | $48.05B | 0.15% |
MLN | 0.44% | $513.44M | 0.24% |
SCHR | -0.46% | $10.87B | 0.03% |
IBTH | 0.48% | $1.62B | 0.07% |
BNDW | 0.51% | $1.29B | 0.05% |
AGZ | 0.52% | $610.98M | 0.2% |
SHV | -0.53% | $20.75B | 0.15% |
IBTP | -0.58% | $143.68M | 0.07% |
NUBD | 0.61% | $397.19M | 0.16% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IHI | 45.92% | $4.46B | 0.4% |
QDVO | 45.33% | $92.48M | 0.55% |
NULG | 33.68% | $1.65B | 0.26% |
MILN | 32.14% | $127.24M | 0.5% |
IMTM | 31.87% | $3.09B | 0.3% |
THRO | 31.78% | $4.95B | 0.6% |
TMFC | 31.75% | $1.51B | 0.5% |
MGK | 31.62% | $27.62B | 0.07% |
OMFL | 31.55% | $4.95B | 0.29% |
QUAL | 31.54% | $53.38B | 0.15% |
QQQI | 31.51% | $2.85B | 0.68% |
XHE | 31.41% | $168.87M | 0.35% |
NANC | 31.39% | $227.25M | 0.74% |
VUG | 31.26% | $177.37B | 0.04% |
SNPE | 31.25% | $1.94B | 0.1% |
CGGO | 31.19% | $6.43B | 0.47% |
JGRO | 31.17% | $6.49B | 0.44% |
VOOG | 31.15% | $18.22B | 0.07% |
EFG | 31.07% | $13.14B | 0.36% |
IGPT | 31.01% | $485.68M | 0.58% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -25.41% | $94.90M | 0.59% |
VIXY | -22.09% | $200.94M | 0.85% |
VIXM | -19.25% | $22.99M | 0.85% |
TPMN | -15.77% | $30.86M | 0.65% |
BTAL | -14.96% | $310.24M | 1.43% |
SOYB | -14.58% | $26.41M | 0.22% |
FTSD | -11.40% | $233.24M | 0.25% |
CANE | -10.74% | $11.17M | 0.29% |
USDU | -8.18% | $129.88M | 0.5% |
CMBS | -7.82% | $456.43M | 0.25% |
STOT | -7.52% | $254.22M | 0.45% |
BSMW | -7.17% | $107.58M | 0.18% |
BILZ | -6.51% | $852.10M | 0.14% |
UGA | -6.43% | $75.20M | 0.97% |
CORN | -6.18% | $43.88M | 0.2% |
CLIP | -6.16% | $1.51B | 0.07% |
XONE | -6.08% | $629.16M | 0.03% |
IVOL | -6.02% | $341.06M | 1.02% |
FXY | -5.82% | $798.58M | 0.4% |
DBE | -5.62% | $53.74M | 0.77% |
Yahoo
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Yahoo
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
Yahoo
Edwards Lifesciences is slated to unveil its second-quarter earnings this month, and analysts are projecting a double-digit decrease in earnings.
SeekingAlpha
Thrivent Mid Cap Stock Fund trailed the Russell Midcap Index during the quarter and underperformed over the last 12 months.
MarketWatch
Edwards Lifesciences Corp. stock underperforms Tuesday when compared to competitors
Yahoo
Edwards Lifesciences (NYSE:EW) experienced a 7.91% price increase over the last quarter, amidst significant developments. On June 30, 2025, the company was removed from several Russell indices, potentially affecting its visibility among growth-focused funds and possibly influencing institutional investment. However, Edwards Lifesciences bolstered its market position with key product approvals, including Health Canada's approval of its EVOQUE tricuspid valve replacement system and the FDA's...